Physical Activity on Neurophysiologic Gene Expression Profiles of Chronic Low Back Pain (PROPEL)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03637998 |
|
Recruitment Status :
Active, not recruiting
First Posted : August 20, 2018
Last Update Posted : September 28, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Chronic Low Back Pain Self-Management | Behavioral: Problem-solving Pain to Enhance Living Well (PROPEL) | Not Applicable |
Chronic low back pain (cLBP) is the second most frequent chronic pain condition in the United States and results in billions of dollars each year in health care expenses, disability and lost productivity. A major factor that contributes to the refractory nature of cLBP is enhanced pain sensitivity, which is an altered state of pain processing that amplifies pain sensation and impairs descending pain inhibition. Enhanced pain sensitivity in patients who develop cLBP is associated with altered expression of pro-nociceptive and inflammatory genes. On the other hand, regular physical activity of at least moderate intensity for 150 or more minutes per week is recommended to reduce pain severity and improve function in individuals with cLBP. Therefore, a deeper mechanistic understanding of the effect of physical activity on the neurophysiologic and gene transcription alterations that characterize cLBP may inform more specific treatment options to optimize pain reduction and reduce the risk of pain chronicity.
The purpose of this longitudinal cohort pilot study is to examine the feasibility, acceptability, and preliminary efficacy of the Problem-solving Pain to Enhance Living Well (PROPEL) self-management (SM) intervention on cLBP. This pre-post intervention study will recruit 40 community dwelling adults (age 18 - 60 years old) with cLBP. They will receive electronic video modules focused on cLBP SM knowledge and weekly phone consultations to facilitate monitoring and problem-solving. All participants will be assessed for primary outcomes including cLBP SM behaviors, physical activity, pain severity and interferance, and pain sensitivity at baseline and every 2 weeks for 12 weeks. The study will examine differential neurophysiologic and gene expression profiles between participants with cLBP at 12-weeks post-intervention and correlate these outcome measures to total duration of physical activity.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 40 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Supportive Care |
| Official Title: | The Impact of Physical Activity on the Neurophysiologic and Gene Expression Profiles of Chronic Low Back Pain: A Longitudinal Study Protocol |
| Actual Study Start Date : | September 21, 2018 |
| Estimated Primary Completion Date : | June 2022 |
| Estimated Study Completion Date : | June 2022 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: PROPEL
The Problem-solving Pain to Enhance Living Well (PROPEL) intervention entails each participant watching 10 video modules via REDCap. These modules include: (1) pain neurophysiology, (2) catastrophizing, (3) stress reactivity, (4) fear of movement, (5) progressive relaxation, (6) deep breathing, (7) guided imagery, (8) heat, ice and stretching, (9) strategies for physical activity self-activation and (10) problem-solving.
|
Behavioral: Problem-solving Pain to Enhance Living Well (PROPEL)
PROPEL incorporates evidence-based, standard of care methods to promote physical activity among individuals with pain, and tools to improve knowledge, skills and confidence to cope with cLBP. The focus is self-management of cLBP. All eligible participants will then undergo baseline data collection, which entails completion of study questionnaires, quantitative sensory testing (QST) and venipuncture for collection of a blood specimen. Participants will be provided with the information to access the PROPEL intervention. All participants will be asked to complete questionnaires at 2, 4, 6, 8, and 10 weeks following baseline testing. At 12 weeks, participants will be scheduled for a final data collection visit, which will follow the same procedures as the baseline visit. |
- Change in physical activity [ Time Frame: Baseline, 2, 4, 6, 8, 10 and 12 weeks ]Fitbit for activity tracker
- Change in gene expression profiles [ Time Frame: Baseline and 12 weeks post-intervention ]RNA sequencing
- Change in pain sensitivity [ Time Frame: Baseline and 12 weeks post-intervention ]Quantitative sensory testing
- Relationship between pain self-management and pain severity [ Time Frame: Baseline, 2, 4, 6, 8, 10 and 12 weeks ]Change over time through questionnaires
- Relationship between pain self-management and pain interferance [ Time Frame: Baseline, 2, 4, 6, 8, 10 and 12 weeks ]Change over time through questionnaires
- Relationship between pain self-management and quality of life [ Time Frame: Baseline, 2, 4, 6, 8, 10 and 12 weeks ]Change over time through questionnaires
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 60 Years (Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- be 18-60 years of age;
- have nonspecific cLBP (≥4 on the numeric rating scale; NRS) present for at least 3 out of the last 6 months and ≥ half the days in the past 6 months;
- comprehend English (due to lack of reliability and validity of study instruments and the intervention in non-English populations).
- Have daily access to a computer, tablet or smartphone with access to internet
- Have less than 150 minutes of moderate physical activity a week
- Be willing to wear activity tracker for 12 weeks
Exclusion Criteria:
- Chronic pain at another site or associated with a painful condition (eg., fibromyalgia, neuropathy, rheumatoid arthritis)
- history of comorbidities that affect sensorimotor function (eg., multiple sclerosis, cancer, spinal cord injury, diabetes)
- previous spinal surgery within last 1 year
- presence of neurological deficits such as weakness in the lower extremities (motor strength 4/5 of quads, glutes, hamstrings, EHL)
- bowel or bladder dysfunction such as difficulty voiding or incontinence
- sciatica or (+) leg raise
- positive Romberg test
- being pregnant or within 3 months postpartum
- history of psychological disorders (major depression, bipolar disorder, schizophrenia)
- identification of any "red flag" condition in the volunteer's past medical history that suggests specific LBP as determined by Dr. Kim such as conditions or medications that can affect pain sensitivity
- injury to non-dominant hand or presence of open skin lesions, disturbed sensation, carpal tunnel or rash
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03637998
| United States, Connecticut | |
| University of Connecticut | |
| Storrs, Connecticut, United States, 06269 | |
| Principal Investigator: | Kyounghae Kim, PhD | University of Connecticut | |
| Study Director: | Angela Starkweather, PhD | University of Connecticut |
| Responsible Party: | Wanli Xu, Assistant Professor, University of Connecticut |
| ClinicalTrials.gov Identifier: | NCT03637998 |
| Other Study ID Numbers: |
H18-086 5P20NR016605 ( U.S. NIH Grant/Contract ) |
| First Posted: | August 20, 2018 Key Record Dates |
| Last Update Posted: | September 28, 2021 |
| Last Verified: | September 2021 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | All of the individual participant data that are part of National Institute of Nursing Research (NINR) designated common data elements collected during the trial, after de-identification have been submitted to NIH repository at the Common Data Repository for Nursing Science (cdRNS). Data can be accessed by directly submitting requests at that website. When will data be available (start and end dates)? Immediately. No end date. With whom? Anyone who wishes to access the data and creates an account on cdRNS.nih.gov. By what mechanism will data be made available? Data are available at cdRNS.nih.gov |
| Time Frame: | Within 2 years |
| Access Criteria: | Requests will be submitted through the cdRNS website |
| URL: | https://cdrns.nih.gov |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Gene expression Quantitative Sensory Testing Genotyping |
|
Back Pain Low Back Pain Pain Neurologic Manifestations |

